INTRODUCTION
Hepatitis B virus (HBV) infection is a major global public health problem. It is estimated that 240 million people are chronically infected with HBV worldwide and approximately 780000 deaths each year are attributed to hepatitis B [1] . Chronic hepatitis B (CHB) can cause severe liver inflammation and fibrosis, ultimately resulting in more serious complications such as cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC) [2] . In patients with CHB, the presence of hepatitis B e antigen (HBeAg) indicates active HBV replication and more severe infection.
Therefore, it may be useful to monitor HBeAg levels in patients to determine treatment response, as HBeAg seroconversion in HBeAg-positive patients with sustained undetectable HBV DNA may be considered as a potential end point in the treatment of CHB [3] . Currently approved therapies for CHB include two immune-based interferons [interferon-a (IFN-a) and pegylated IFN a (PEG-IFN a-2a or a-2b)] and five antiviral nucleos(t)ide analogs (NAs), namely adefovir, entecavir, lamivudine, telbivudine, and tenofovir. These antivirals do not completely eradicate HBV, and hence the efficacy of these therapies is still unsatisfactory [2, 4] . At present, NAs are most commonly used in
HBeAg-positive patients with CHB. HBeAg seroconversion in patients with CHB is associated with favorable long-term outcomes, such as disease remission, lower incidence of cirrhosis and HCC, and higher survival rates [3, 5, 6] . A number of systematic literature reviews (SLRs) and meta-analyses have been published on the efficacy of NAs for the treatment of CHB [4, [7] [8] [9] [10] . Although these meta-analyses evaluated the efficacy of NAs, their scope was limited primarily to direct comparisons of NAs without considering indirect evidence using a common comparator between two NAs, which
were not compared against each other in a randomized controlled trial (RCT). There is only one published meta-analysis which used a mixed-treatment comparison of NAs [8] [11, 12] . To address this need, we have performed SLR and NMA to compare the efficacy of the approved NAs. The aim of this meta-analysis was to assess the efficacy of telbivudine compared to adefovir, entecavir, lamivudine, and tenofovir in nucleos(t)ide-naïve HBeAg-positive patients with CHB.
METHODS
This SLR followed standard systematic review methodology endorsed by the Cochrane Collaboration [13] and the National Institute for Health and Care Excellence (NICE) in the UK [14] . The SLR was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15] . This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. 
Inclusion and Exclusion Criteria

First-Level Screening of Citations
All the studies retrieved from the literature search were screened based on the title and abstract supplied with each citation. The inclusion/exclusion criteria were uniformly applied across all the studies. Two independent reviewers for English and two for Chinese publications screened the retrieved abstracts, and any discrepancies between reviewers were reconciled by a third independent reviewer. Studies that did not meet the eligibility criteria were excluded, and reasons for exclusion were documented.
Full-text copies of all references that met the inclusion criteria were then downloaded.
Second-Level Screening of Citations
The inclusion/exclusion criteria were uniformly applied across all the full-text publications. The same two reviewers for English and two for Chinese publications screened all the manuscripts, and any discrepancies between reviewers were reconciled by a third independent reviewer. Studies that did not meet the eligibility criteria were excluded, and reasons for exclusion were documented. Studies that met the inclusion criteria were subjected to data extraction.
Data Extraction
The same reviewers extracted data independently in a data extraction template, with any discrepancies resolved by a third independent reviewer. Data were extracted based on different information from a study, such as objectives, methods, inclusion and exclusion criteria, baseline demographic and clinical characteristics, interventions, efficacy outcomes, and conclusion. Studies with multiple publications were linked to one another and extracted as a single study. The full texts of the relevant articles were examined to determine the relevance of data on study objectives, design, inclusion/exclusion criteria, patients, interventions, and efficacy outcomes. The RCTs that met the inclusion criteria for the review were critically appraised for quality based on the recommendations by NICE [14] .
Assessments of End Points
The primary end point of the analysis was HBeAg seroconversion in patients with CHB.
HBeAg seroconversion was defined as HBeAg loss and the appearance of anti-HBe antibodies.
Secondary end points included rates of HBeAg loss, normalization of ALT, undetectable HBV DNA levels, and HBsAg loss and seroconversion.
HBV DNA levels less than 1000 copies/mL (HBV DNA \200, 300, 400, 500 copies/mL, etc.)
reported in studies were pooled together and analyzed for the undetectable HBV DNA end point. The study end points were analyzed at 1-year (48-52 weeks) and 2-year (96-104 weeks) time points.
Statistical Analysis
The 
RESULTS
Search Results
The results of the literature search are summarized in Fig. 1 . The search yielded 5499 publications. Of these, 1719 studies were duplicates due to the overlap of records across the databases. All 3780 studies went through first-level screening (title/abstract screening).
Following this, 432 publications were found to be eligible. These were subjected to second-level screening (full-text screening) and there were 86 publications remaining. The number of publications excluded at each level of screening and the corresponding reasons for exclusion are presented in Fig. 1 . A total of 24 Chinese publications were additionally identified through bibliographic search (three of these were duplicate Chinese articles), resulting in a total of 107 publications. As some publications were linked to one another, the final list of publications included 75 studies (37 English publications and 38 Chinese publications).
Study Characteristics
Of the 75 included studies, 29 (39%) English and 32 (43%) Chinese language studies were active controlled. Only nine (12%) studies in total were placebo controlled. Of the remaining five studies, one compared lamivudine with untreated controls and four were dose-ranging studies. Of the 38 Chinese language studies, 29
(76%) were single center, whereas of the 37 English language studies, 26 (70%) were multi-center. Almost all of the Chinese language studies were phase IV trials and 14 (38%) of the English language studies were phase III, with only four studies reported to be In the included RCTs, lamivudine was the most commonly assessed comparator accounting for 24 studies. This was followed by placebo, which was the comparator in 12 of the included studies. NAs were assessed as monotherapy in 58 of the included studies.
Overall, 19% of the included studies may be at risk of bias: of these, 15% due to blinding methodology and 4% due to statistical analysis. Table S1 in the online supplementary material. The sample size of the included studies ranged from 14 to 921 [18, 19] . The median age of the patients ranged from 24 to 44 years [10, 20] . The majority of studies recruited primarily male patients; 37% of these studies reported a male population greater than 70%. The studies reported ALT levels above 100 IU/L. Of 11 studies which reported information on HBV genotypes, more than 50% of the recruited patients had genotype C as the major viral genotype, indicating that the majority of the study population represented is of Southeast Asian descent [21] . The proportion of patients with genotype B ranged from 8% to 41% among the included studies which reported information on HBV genotype [22, 23] . Table S2 in the online supplementary material shows the total numbers of patients in each treatment regimen and the corresponding numbers of patients with reported HBeAg seroconversion, HBeAg loss, ALT normalization, and undetectable HBV DNA. that telbivudine was superior to adefovir, entecavir, and lamivudine (Fig. 3a) . The relative efficacy outcomes of telbivudine versus other NAs at the 2-year time point were not statistically significant. There were a relatively small number of studies (14 studies) which reported outcomes at the 2-year time point.
HBeAg Seroconversion
HBeAg Loss
Thirty studies reported HBeAg loss results. The NMA on relative efficacy at the 1-year time point showed that telbivudine was superior to entecavir and lamivudine for HBeAg loss in patients with CHB (Fig. 3b) . The relative efficacy of NAs at the 2-year time point yielded no statistically significant results.
ALT Normalization
Thirty-two studies reported ALT normalization results. The relative efficacy of NAs at the 1-year time point is presented in Fig. 3c . The NMA demonstrated that telbivudine was superior to lamivudine in ALT normalization.
Undetectable HBV DNA
There were 34 studies that reported rates of undetectable HBV DNA at 1 year of treatment.
The relative efficacy of NAs at the 1-year time point (Fig. 3d ) demonstrated that telbivudine was superior to adefovir and lamivudine in suppressing HBV DNA levels. Tenofovir was superior to telbivudine in suppressing HBV DNA levels.
Analysis of Heterogeneity
None of the factors including study location, age, and baseline HBV DNA was found to affect the results.
DISCUSSION
This comprehensive and up-to-date NMA analyzed both direct and indirect evidence for the comparative efficacies of NAs. To ensure as comprehensive an approach as possible, we incorporated both English and Chinese undetectable HBV DNA and persistently normal ALT levels [3, 24] . HBeAg seroconversion is associated with favorable long-term outcomes, including reduced risk of cirrhosis or HCC [3] . A long-term study in patients with CHB showed that during a median follow-up of approximately nine years after spontaneous HBeAg seroconversion, the majority (67%) of patients had sustained remission [5] . Another study reported that the rate of fibrosis progression was lower in patients The present analysis also demonstrated that telbivudine was superior to entecavir and lamivudine for inducing HBeAg loss, and to lamivudine in ALT normalization. With regard to reducing HBV DNA levels, telbivudine demonstrated superior efficacy as compared to adefovir and lamivudine, and similar efficacy to entecavir. Outcomes at 1 year showed that tenofovir was superior to telbivudine in suppressing HBV DNA levels. However, there were only two studies with tenofovir which reported undetectable HBV DNA at the 1-year time point. Data from an earlier meta-analysis showed that compared to other NAs, tenofovir had the highest probability of achieving HBeAg seroconversion after 1 year of treatment. Tenofovir also showed significantly higher HBV DNA reduction than the other NAs. Entecavir was significantly superior to adefovir and lamivudine, whereas telbivudine showed superior efficacy than lamivudine [8] . However, this meta-analysis by Wiens et al. has two major limitations that were acknowledged by the authors. First, a random-effect meta-analysis software (ADDIS) was used, unlike the current analysis that was performed using WinBUGS 1.4, a widely accepted software for conducting Bayesian NMA. Second, the previously published analysis included data from only nine RCTs of 48-52 weeks duration. Hence, results from this published analysis cannot be extrapolated or generalized to real-life situations.
Results from a prospective study showed that treatment intensification (Roadmap approach) with adefovir add-on therapy in patients with suboptimal virologic response (HBV DNA C300 copies/mL) after 24 weeks of telbivudine treatment significantly improved efficacy outcomes at 2 years. This shows that adjustment of treatment strategy may be useful for patients with suboptimal virologic response to telbivudine treatment [23] . 
